

**TABLE 191: FATIGUE**

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-1	1	(6) SOF12 + LDV12	44	214	21%
		(10) SOF12 + LDV12 + RBV12	79	217	36%
		(11) SOF24 + LDV24 + RBV24	82	217	38%
Buti et al., 2014 OPTIMIZE	1	(32) T12 PR24-48 RGT q8	181	371	49%
		(33) T12 PR24-48 RGT q12	185	369	50%
Feld et al., 2014 SAPPHERE-I	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	164	473	35%
Ferenci et al., 2014 PEARL-III	1b	(14) PAR/RIT12 + OMB12 + DAS12	45	209	22%
Ferenci et al., 2014 PEARL-IV	1a	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	46	100	46%
Fried et al., 2013 PILLAR	1	(1) PR48	37	77	48%
		(42) SIM12 PR24-48 RGT	32	77	42%
Gane et al., 2013-1 ELECTRON	2+3	(3) SOF12 + RBV12	1	10	10%
		(40) SOF12 + PR12	5	11	45%
Gane et al., 2013-3 ELECTRON	1	(3) SOF12 + RBV12	12	25	48%
Gane et al., 2014-1 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	6	25	24%
Jacobson et al., 2014 QUEST-1	1	(1) PR48	53	130	41%
		(42) SIM12 PR24-48 RGT	110	264	42%
Jacobson et al., 2011 ADVANCE	1	(1) PR48	206	361	57%
		(32) T12 PR24-48 RGT q8	207	363	57%
Kohli et al., 2015	1	(6) SOF12 + LDV12	2	20	10%
Kowdley et al., 2013 ATOMIC	1	(40) SOF12 + PR12	25	52	48%
Kowdley et al., 2014 ION-3	1	(6) SOF12 + LDV12	49	216	23%
		(8) SOF8 + LDV8	45	215	21%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
		(9) SOF8 + LDV8 + RBV8	75	216	35%
Lalezari et al. et al., 2015	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	18	38	47%
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	192	327	59%
Lawitz et al., 2013 FISSION	2+3	(3) SOF12 + RBV12	92	256	36%
		(70) PR24	134	243	55%
Lawitz et al., 2014 LONESTAR	1	(8) SOF8 + LDV8	0	20	0%
		(9) SOF8 + LDV8 + RBV8	1	21	5%
		(6) SOF12 + LDV12	1	19	5%
Lawitz et al., 2013-1 PROTON	1	(1) PR48	14	26	54%
		(41) SOF12 PR24-48 RGT	32	47	68%
Lawitz et al., 2013-2 PROTON	2+3	(40) SOF12 + PR12	9	25	36%
Lawitz et al., 2015-1 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	5	29	17%
		(59) GRZ18 + ELB18 (50 mg q.d.)	5	31	16%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	9	31	29%
		(65) GRZ18 + ELB18 (50 mg q.d.) + RBV18	9	32	28%
Manns et al., 2014 HALLMARK-	1b	(17) DCV24 + ASU24	43	205	21%
Manns et al., 2014 QUEST-2	1	(1) PR48	56	134	42%
		(42) SIM12 PR24-48 RGT	94	257	37%
Marcellin et al., 2011	1	(32) T12 PR24-48 RGT q8	30	82	37%
		(33) T12 PR24-48 RGT q12	31	79	39%
Molina et al., 2015-1+3+4 PHOTON-2	1+3+4	(4) SOF24 + RBV24	40	200	20%
Molina et al., 2015-2 PHOTON-2	2	(3) SOF12 + RBV12	5	19	26%
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	3	10	30%
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	4	25	16%
		(71) SOF24 + RBV (low dose) 24	6	25	24%
Osinusi et al., 2015	1	(6) SOF12 + LDV12	5	50	10%
Poordad et al., 2011 SPRINT2	1	(1) PR48	217	363	60%
		(46) B24 PR28-48 RGT	196	368	53%
Rodriguez-Torres et al., 2015	1+2+3+4	(40) SOF12 + PR12	8	23	35%
Sulkowski et al., 2015-1 C-WORTHY	1	(23) GRZ12 + ELB12 + RBV12	23	86	27%
		(57) GRZ12 + ELB12 (50 mg q.d.)	10	43	23%
		(61) GRZ8 + ELB8 (50 mg q.d.) + RBV8	14	30	47%
Sulkowski et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	2	30	7%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	2	29	7%
Sulkowski et al., 2014-1 <sup>a</sup>	2+3	(3) SOF12 + RBV12	24	68	35%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Sulkowski et al., 2014-2	1	(4) SOF24 + RBV24	41	114	36%
Sulkowski et al., 2014	1	(19) DCV12 + SOF12	16	41	39%
Sulkowski et al., 2013-1+2 <sup>#b</sup>	1	(1) PR48	9	22	41%
		(39) T12 PR48 q8	16	38	42%
Sulkowski et al., 2013	1	(1) PR48	12	34	35%
		(50) B44 PR48	24	64	38%
Zeuzem et al., 2015-1+2+3 C-EDGE	1+4+6	(22) GRZ12 + ELB12	49	316	16%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

<sup>a</sup> Data for ineligible treatment for genotype 3, (3) SOF12 + RBV12, are included.

<sup>b</sup> Data for ineligible participants who receive efavirenz-based antiretroviral and 1,125 mg of telaprevir every 8 hours are also included.